Author

Tingting Wu

Western UniversityORCID 0000-0003-4375-6820Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Alyssa WuiD· 2 shared Ilka U. HeinemanniD· 2 shared Jenica H. KakadiaiD· 2 shared Mallory I. Frederick· 2 shared Owen F.J. HoveyiD· 2 shared Shawn S.‐C. LiiD· 2 shared Courtney VossiD· 1 shared Kyle YangiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alyssa WuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacological inhibition of LIN28A promotes imatinib sensitivity in CML resistance

Owen F.J. Hovey, Alyssa Wu, Tingting Wu, Jenica H. Kakadia, Mallory I. Frederick, Ilka U. Heinemann, Shawn Li

This study shows that inhibiting LIN28A with LIN28i-1632 enhances imatinib sensitivity in imatinib-resistant CML cells by reducing BCR-ABL abundance and disrupting the AKT survival pathway.

bioRxiv · Apr 29, 2026 · PreprintCancer Biology

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance

Owen F.J. Hovey, Mallory I. Frederick, Quan M. Quach, Jenica H. Kakadia, Alyssa Wu, Kyle Yang, Tingting Wu, Xiang Ruan, Tomonori Kaneko, Courtney Voss, Ilka U. Heinemann, Shawn S.‐C. Li

This study identifies LIN28A as a mediator of imatinib resistance in CML by reprogramming the kinome and phosphoproteome, with potential therapeutic implications for overcoming resistance.

Molecular & Cellular Proteomics · Jan 20, 2026Peer-reviewedCancer Biology